Stay Informed
Global Health Technologies Coalition

advancing innovation to save lives

GHTC unveils policy recommendations for new administration and Congress

GHTC releases a new policy report which provides an agency-by-agency blueprint for US policymakers to supercharge global health R&D in the wake of the COVID-19 pandemic that has revealed both the sector’s chronic neglect and amazing potential. 

Learn more

GHTC report examines COVID-19 impacts

GHTC released a recent report exploring how COVID-19 is impacting the global health R&D sector. Based on qualitative interviews, it looks at both immediate impacts, including disruptions to research and diversion of funding and expertise, as well as long-term challenges and opportunities that may reshape the sector in the years to come.

Learn more

Member Spotlight: EGPAF

Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) is a global leader in the fight against pediatric HIV/AIDS and has reached more than 24 million women with services to prevent transmission of HIV to their babies. It recently published a brief on accelerating access to optimal child-friendly antiretroviral formulations for children living with HIV based on lessons learned from eight sub-Saharan African countries.

View brief

GHTC works to save and improve lives by encouraging the research and development of essential health technologies. We bring together more than 30 nonprofit organizations, academic institutions, and aligned businesses to advance policies to accelerate the creation of new drugs, vaccines, diagnostics, and other tools that bring healthy lives within reach for all people.

Members
0
Members
Health Technologies in Development by Members
0
Health Technologies in Development by Members
Countries where Members Work
0
Countries where Members Work
Donor Governments Supporting Member Projects
0
Donor Governments Supporting Member Projects

Why we're needed

Health technologies have the potential to save millions of lives. New tools are needed to slow the global threat of diseases, including HIV/AIDS, malaria, tuberculosis, and neglected tropical diseases, and tackle many other pressing health needs. For diseases and conditions primarily affecting people in the world’s poorest places, there is little to no commercial market to spur R&D. Strong investment and innovative solutions are needed to catalyze the development of new technologies to bring health and opportunity within reach for all people.

Learn More
GHTC delivers statement on AMR at HHS WHA listening session
CDC/ Melissa Dankel
May 13, 2021

GHTC delivers statement on AMR at HHS WHA listening session

GHTC delivered a statement at the US Department of Health and Human Services (HHS) World Health Assembly (WHA) Stakeholder Listening Session calling on the US government to increase investment in developing new antimicrobials, vaccines, diagnostics, and other tools to combat antimicrobial resistance (AMR), including by supporting the Global Antibiotic Research and Development Partnership.

Learn more
GHTC delivers statement on GSPOA at HHS WHA listening session
PATH/Gabe Bienczycki
May 13, 2021

GHTC delivers statement on GSPOA at HHS WHA listening session

GHTC delivered a statement at the US Department of Health and Human Services (HHS) World Health Assembly (WHA) Stakeholder Listening Session on the global strategy and plan of action on public health, innovation and intellectual property (GSPOA). GHTC encouraged the US delegation to support global efforts to strengthen regulatory capacity and local production of health technologies in low- and middle-income countries and push for the World Health Organization to develop target product profiles for key missing tools to address health threats.

Learn more
GHTC delivers statement on Immunization Agenda 2030 at HHS WHA listening session
PATH/Gabe Bienczycki
May 13, 2021

GHTC delivers statement on Immunization Agenda 2030 at HHS WHA listening session

GHTC delivered a statement at the US Department of Health and Human Services (HHS) World Health Assembly (WHA) Stakeholder Listening Session encouraging the US delegation to work with the World Health Organization and member states to strengthen mechanisms to define vaccine-related research priorities informed by user needs. GHTC also called on the US government to robustly invest in vaccine development for priority health challenges and support research on the full spectrum of product needs, including vaccine administration tools and storage and delivery innovations.

Learn more
View all News
View all Events
View all Breakthroughs Blog
Our Members work to improve health worldwide